Loading...

CADL CANDEL THERAPEUTICS INC US FDA Inspections 8-K Filing

CNDL

CDL

CANDEL THERAPEUTICS INC

(CADL)

2023 8-K

Show Summary

Show Summary

Equity Offerings

Product Expansion

Product Expansion

Financial Statements

Clinical Trials

Clinical Trial Results

Financial Results

Positive Trial Results

Cash Position Update

Earnings Report

Financial Results

Clinical Trial Update

Financial Results

Annual Meeting of Stockholders

Bylaws Amendment

Clinical Trial Data Announc...

Financial Results Announcement

Poster Presentations at Onc...

FDA Orphan Drug Designation

Product Development

Clinical Trial Results

Financial Results Announcement

Conference Presentation

FDA Fast Track Designation ...

Appointment of Interim CFO

Compliance Regained

Departure of CFO

FDA Fast Track Designation ...

Restructuring Plan

Financial Results Announcement

Preclinical Data Presentation

Clinical Trial Results

Clinical Trial Update

Financial Results Announcement

Annual Meeting of Stockholders

Clinical Trial Results

Appointment of Director

Presentation at ASGCT Annua...

Financial Results Announcement

Annual Meeting of Stockholders

FDA Fast Track Designation ...

Financial Results Announcement

Change of Clinical Trial En...

External Links:

Candel Therapeutics, Inc. announced that the FDA has granted fast track designation for CAN-2409 + valacyclovir in combination with pembrolizumab for non-small cell lung cancer patients.

AI Assistant

CANDEL THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.